Processing...
Clinical Trials for Esophageal Cancer
Search
Search
There are 86 active trials for advanced/metastatic esophageal cancer.
Click on a trial to see more information.
86 trials meet filter criteria.
Sort by:
HealthScout AI summary: Adults with unresectable locally advanced or metastatic CLDN18.2-positive solid tumors (e.g., gastric/GEJ, pancreatic, esophageal adenocarcinoma, biliary tract cancers) after prior systemic therapy receive BL-M05D1, an IV CLDN18.2-targeting antibody–drug conjugate linking a cathepsin B–cleavable topoisomerase I inhibitor payload, given every 21 days. Key eligibility includes measurable disease, ECOG 0–1, adequate organ function, and prior appropriate targeted/immunotherapy for actionable biomarkers.
ClinicalTrials.gov ID: NCT07021066
HealthScout AI summary: Adults with unresectable, locally advanced, or metastatic gastric/GEJ/esophageal or pancreatic adenocarcinoma expressing CLDN18.2 (IHC ≥1+ in ≥50%) receive LB1908, an autologous CLDN18.2-directed CAR-T therapy, as monotherapy in second or later lines or as consolidation after disease control on first-line chemotherapy. Key exclusions include prior cellular/gene therapy, significant effusions/bleeding risk, active autoimmune disease requiring immunosuppression, unstable cardiac/infectious disease, and active CNS disease (except stable treated brain mets in monotherapy cohorts).
ClinicalTrials.gov ID: NCT05539430
HealthScout AI summary: Adults with CLDN18.2-positive advanced/metastatic gastric, GEJ, esophageal, or pancreatic adenocarcinoma after prior systemic therapy receive AZD5863 monotherapy, a CLDN18.2×CD3 T cell–engaging bispecific antibody, via IV or SC administration. Trial focuses on dose finding and preliminary efficacy with RECIST-measurable disease and ECOG 0–1 required.
ClinicalTrials.gov ID: NCT06005493
HealthScout AI summary: Adults <70 with metastatic gastrointestinal or peritoneal tumors (esophageal, gastric, colorectal, liver, pancreatic) refractory to standard therapy, with at least one lesion amenable to intratumoral injection. Single intratumoral dose of vvDD-hIL2-2-RG-1, an oncolytic vaccinia virus (double-deleted TK/VGF) engineered to express membrane-tethered IL-2 to promote localized T-cell activation and oncolysis; no combination therapy in this first-in-human, single-dose escalation.
ClinicalTrials.gov ID: NCT07001592
HealthScout AI summary: Adults with metastatic/unresectable solid tumors after standard therapy, with dose expansion in squamous histologies (sqNSCLC with/without NRF2 or CUL3 mutations, HNSCC, ESCC post–platinum and checkpoint inhibitor), receive the investigational KEAP1 activator VVD-130037 orally as monotherapy or combined with docetaxel or paclitaxel. VVD-130037 is a covalent, allosteric molecular glue that enhances KEAP1–CUL3–mediated NRF2 degradation to counter NRF2-driven oncogenesis and taxane resistance; patients with KEAP1 nonsense/frameshift mutations are excluded.
ClinicalTrials.gov ID: NCT05954312
HealthScout AI summary: Adults with incurable, locally advanced/metastatic Nectin-4–positive solid tumors—emphasizing relapsed/refractory urothelial cancer—receive RNDO-564 weekly as monotherapy or combined with pembrolizumab every 3 weeks. RNDO-564 is a fully human CD28 × Nectin-4 costimulatory bispecific antibody intended to deliver localized CD28 T‑cell costimulation at Nectin-4–expressing tumors; early cohorts include multiple Nectin-4–associated cancers, with randomized dose-optimization in urothelial cancer.
ClinicalTrials.gov ID: NCT07218003
HealthScout AI summary: Adults with advanced/metastatic urothelial carcinoma or squamous cell carcinomas (lung, esophagus, cutaneous, head/neck, anogenital) after standard therapies receive single‑agent EVOLVE104, a trispecific T‑cell engager targeting ULBP2/5/6 with CD3 binding and CD2 costimulation. Open‑label dose escalation and expansion assess safety, PK, and preliminary efficacy, with treatment continued until progression or intolerance.
ClinicalTrials.gov ID: NCT07217171
HealthScout AI summary: Adults with advanced/metastatic urothelial/bladder cancer, NSCLC, HNSCC, esophageal cancer, or pancreatic adenocarcinoma (ECOG 0–1) receive PF-08046876, an ITGB6-targeted antibody–drug conjugate delivering a topoisomerase I payload, as IV monotherapy after prior standard therapy (≤2 prior lines in Part 2). Dose escalation/optimization and tumor-specific expansions assess safety, PK, and preliminary activity; excludes prior camptothecin/topo I ADC exposure and significant GI or pulmonary comorbidities.
ClinicalTrials.gov ID: NCT07090499
HealthScout AI summary: Adults with advanced solid tumors refractory to standard therapy (ECOG 0–1, measurable disease) receive a single intravenous infusion of IDOV-Immune (VM-002), a genetically engineered oncolytic vaccinia virus designed for tumor-selective replication and lysis with immune-stimulating transgenes to enhance antitumor immunity. Key exclusions include prior oncolytic virus therapy, recent vaccinia/smallpox vaccination, active autoimmune disease requiring systemic therapy, significant cardiopulmonary disease, uncontrolled infection, and unstable/untreated CNS metastases.
ClinicalTrials.gov ID: NCT06910657
HealthScout AI summary: Adults with advanced/metastatic FAP-expressing solid tumors (including pancreatic, multiple breast cancer subtypes, platinum-resistant/refractory ovarian, and other FAP-positive GI tumors) and ECOG 0–1 receive intravenous LY4337713, a lutetium-177–labeled small-molecule radioligand targeting fibroblast activation protein on cancer-associated fibroblasts to deliver beta radiation to the tumor microenvironment, on Q4–6 week cycles. Expansion cohorts are tumor-specific after dose escalation/optimization.
ClinicalTrials.gov ID: NCT07213791